Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Two‐Year Outcomes after Utilization of the TAXUS Paclitaxel‐Eluting Stent in Bifurcations and Multivessel Stenting in the ARRIVE Registries

Two‐Year Outcomes after Utilization of the TAXUS Paclitaxel‐Eluting Stent in Bifurcations and... Aims: Examine the incidence of clinical events after utilization of the TAXUS® Express® paclitaxel‐eluting stent (PES) in multivessel and bifurcation coronary stenting in an unselected patient population. Methods and Results: The ARRIVE Program compiled data on 7,492 patients receiving ≥1 TAXUS Express PES, including patients with multivessel stenting (MVS; n = 1,208) and bifurcation stenting (n = 575). Patients were enrolled at procedure start with no mandated inclusion/exclusion criteria; all cardiac events were monitored with independent adjudication of end‐points. Compared to simple use (single vessel/single stent) patients undergoing native intervention (N = 2,698), MVS patients had significantly more baseline comorbidities. Both groups had higher 2‐year rates of mortality (7.3%(MVS) and 7.5%(bifurcation) vs. 4.2%(simple‐use), P < 0.001), myocardial infarction (5.5% and 4.6% vs. 2.2%, P < 0.001 and P = 0.002), target vessel revascularization (15.5% and 14.8% vs. 7.7%, P < 0.001), and Academic Research Consortium definite/probable stent thrombosis (4.3% and 4.4% vs. 1.4%, P < 0.001) than the simple‐use group. Conclusions: ARRIVE multivessel and bifurcation stenting patients have significantly higher clinical risk through 2 years compared to simple‐use patients. In the absence of large randomized controlled trials in these populations, ARRIVE provides important insight into clinical outcomes over an extended period of time. (J Interven Cardiol 2011;24:342–350) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Two‐Year Outcomes after Utilization of the TAXUS Paclitaxel‐Eluting Stent in Bifurcations and Multivessel Stenting in the ARRIVE Registries

Download PDF
9 pages

Loading next page...
 
/lp/wiley/two-year-outcomes-after-utilization-of-the-taxus-paclitaxel-eluting-ECQsp29ShF

References (28)

Publisher
Wiley
Copyright
©2011, Wiley Periodicals, Inc.
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2011.00646.x
pmid
21492221
Publisher site
See Article on Publisher Site

Abstract

Aims: Examine the incidence of clinical events after utilization of the TAXUS® Express® paclitaxel‐eluting stent (PES) in multivessel and bifurcation coronary stenting in an unselected patient population. Methods and Results: The ARRIVE Program compiled data on 7,492 patients receiving ≥1 TAXUS Express PES, including patients with multivessel stenting (MVS; n = 1,208) and bifurcation stenting (n = 575). Patients were enrolled at procedure start with no mandated inclusion/exclusion criteria; all cardiac events were monitored with independent adjudication of end‐points. Compared to simple use (single vessel/single stent) patients undergoing native intervention (N = 2,698), MVS patients had significantly more baseline comorbidities. Both groups had higher 2‐year rates of mortality (7.3%(MVS) and 7.5%(bifurcation) vs. 4.2%(simple‐use), P < 0.001), myocardial infarction (5.5% and 4.6% vs. 2.2%, P < 0.001 and P = 0.002), target vessel revascularization (15.5% and 14.8% vs. 7.7%, P < 0.001), and Academic Research Consortium definite/probable stent thrombosis (4.3% and 4.4% vs. 1.4%, P < 0.001) than the simple‐use group. Conclusions: ARRIVE multivessel and bifurcation stenting patients have significantly higher clinical risk through 2 years compared to simple‐use patients. In the absence of large randomized controlled trials in these populations, ARRIVE provides important insight into clinical outcomes over an extended period of time. (J Interven Cardiol 2011;24:342–350)

Journal

Journal of Interventional Cardiology – Wiley

Published: Aug 1, 2011

There are no references for this article.